Stocktoria
KYNTRA BIO, INC. KYNB
KYNTRA BIO, INC. (KYNB) earns a Piotroski F-score of 3/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $6.4M at a 2848.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| KYNB | KYNTRA BIO, INC. | 3/9 | — | 0.2 | -78.3% |
| KRRO | Korro Bio, Inc. | 2/9 | -13.3 | — | — |
| IMNM | Immunome Inc. | 3/9 | 13.87 | — | — |
| ABEO | ABEONA THERAPEUTICS INC. | 4/9 | -5.75 | 4.5 | — |
| WHWK | Whitehawk Therapeutics, Inc. | 2/9 | 2.98 | — | -72.5% |
| OVID | Ovid Therapeutics Inc. | 1/9 | 0.8 | — | -96.8% |
| XENE | Xenon Pharmaceuticals Inc. | 2/9 | 6.89 | — | — |
About KYNTRA BIO, INC.
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
FAQ
Is KYNB financially healthy?
KYNTRA BIO, INC.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak).
Does KYNB pay a dividend?
No, KYNTRA BIO, INC. does not currently pay a dividend.
How profitable is KYNB?
In FY2025, KYNTRA BIO, INC. had a net margin of 2848.6%.
What is KYNB's P/E ratio?
KYNTRA BIO, INC.'s trailing price-to-earnings (P/E) ratio is about 0.2×, based on its latest annual earnings.
What is the analyst price target for KYNB?
The average Wall-Street price target for KYNTRA BIO, INC. is $43.00, about 505.6% above the recent price, from 1 analysts.
Is KYNB a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on KYNTRA BIO, INC.: a Piotroski F-score of 3/9, a P/E of about 0.2×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.